Search News Year All202620252024202320222021 05/12/2026 Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference Read More 05/06/2026 Zevra Reports First Quarter 2026 Financial Results and Corporate Update Read More 04/22/2026 Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call Read More 03/20/2026 Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) Read More 03/16/2026 Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million Read More 03/09/2026 Zevra Reports Fourth Quarter and Full Year 2025 Financial Results Read More 03/05/2026 Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer Read More 03/02/2026 Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call Read More 02/25/2026 Zevra Therapeutics to Present at the Citizens Life Sciences Conference Read More 02/04/2026 Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ Read More
05/12/2026 Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference Read More
03/20/2026 Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) Read More
03/02/2026 Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call Read More
02/04/2026 Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ Read More
News
Careers
Contacts